Result of AGM and Directorate Change
Updated : 16:29
26 November 2020
Result of AGM and Resignation of Non-Executive Director
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, held its Annual General Meeting ('AGM') today at which all resolutions were passed. Resolutions 1-15 were passed as Ordinary Resolutions and Resolutions 14 and 15 were passed as Special Resolutions.
As previously announced in September 2020, John Hartup the Senior Independent Non-Executive Director, decided not to stand for re-election at the AGM and therefore, he has resigned as a Director of the Company with effect from today, 26 November. Consequently, Anne Hyland has been appointed as the Senior Independent Director and Alan Boyd has been appointed to engage with the workforce on behalf of the board as the designated Non-Executive Director. Both of these appointments are effective from 26 November 2020. The Nomination Committee has also started the search process for a new independent Non-Executive Director.
The voting results at the AGM are given in the table below.
| For | Against | Discretionary | ||
Resolution | Number | % | Number | % | Number |
1. To receive the audited financial statements and the Auditors' and Directors' Reports for the year ended 30 June 2020. | 94,363,546 | 100.00% | 285 | 0.00% | 89,188 |
2. To approve the Directors' Remuneration Report (other than the part containing the Directors' remuneration policy) for the year ended 30 June 2020. | 89,044,191 | 94.28% | 5,404,286 | 5.72% | 4,542 |
3. To declare a final dividend of 5.46p per share for the year ended 30 June 2020. | 94,451,582 | 100.00% | 285 | 0.00% | 1,152 |
4. To re-elect Peter Allen as a Director. | 82,526,572 | 87.38% | 11,918,235 | 12.62% | 8,212 |
5. To re-elect Ian Nicholson as a Director. | 92,566,213 | 98.02% | 1,866,630 | 1.98% | 20,176 |
6. To re-elect Anne Hyland as a Director. | 93,911,041 | 99.45% | 521,802 | 0.55% | 20,176 |
7. To re-elect Alan Boyd as a Director. | 79,091,727 | 83.93% | 15,138,298 | 16.07% | 222,994 |
8. To re-elect Shaun Chilton as a Director. | 93,543,054 | 99.04% | 906,789 | 0.96% | 3,176 |
9. To re-elect Nick Keher as a Director. | 93,258,324 | 98.74% | 1,191,674 | 1.26% | 3,021 |
10. To reappoint PricewaterhouseCoopers LLP | 91,007,732 | 96.36% | 3,438,680 | 3.64% | 6,607 |
11. To authorise the Directors to determine the auditors' remuneration. | 91,800,589 | 97.20% | 2,640,554 | 2.80% | 11,876 |
12. To grant the Company authority to make political donations. | 80,071,917 | 91.21% | 7,715,738 | 8.79% | 6,665,364 |
13. To authorise the Directors to allot shares pursuant to section 551 of the Companies Act 2006. | 93,845,132 | 99.36% | 601,552 | 0.64% | 6,335 |
14. To empower the Directors to disapply pre-emption rights. | 89,624,066 | 94.90% | 4,820,119 | 5.10% | 8,834 |
15. To empower the Directors to disapply pre-emption rights in relation to shares issued in connection with an acquisition or specified capital investment. | 88,456,906 | 93.66% | 5,986,979 | 6.34% | 9,134 |
Note: As at 26 November 2020, Clinigen has 133,028,647 ordinary shares of 0.1 pence each in issue and the total number of voting rights is 133,028,647.
- Ends -
For further information, please contact:
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Nick Keher, Group Chief Financial Officer |
|
|
|
J.P.Morgan Cazenove - Nominated Adviser & Joint Broker | Tel: +44 (0)20 7742 4000 |
James Mitford / Hemant Kapoor |
|
|
|
RBC Capital Markets - Joint Broker | Tel: +44 (0)20 7653 4000 |
Marcus Jackson / Elliot Thomas |
|
|
|
Instinctif Partners
| Tel: +44 (0)20 7457 2020
|
Melanie Toyne Sewell / Phillip Marriage | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and the Asia Pacific region.
Clinigen now has over 1,150 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long term growth regions. The Group works with 21 of the top 25 pharmaceutical companies; interacting with over 18,000 registered users across 115 countries, shipping approximately 6.5 million units in the year.
For more information on Clinigen, please visit www.clinigengroup.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.